Alcami Announces CEO Transition
Bill Humphries to succeed Patrick Walsh as CEO effective June 5th, 2023
Patrick Walsh to remain as Chairman of the Board
Bill Humphries to succeed Patrick Walsh as CEO effective June 5th, 2023
Patrick Walsh to remain as Chairman of the Board
Alcami Corporation today announced the appointment of Jamie Iudica to Chief Manufacturing Officer.
Alcami Corporation announces the appointment of Katie Schlipp to the role of President of...
65,000-square-foot facility to provide a broad range of cGMP pharmaceutical and biologics storage...
The completion of Phase II expansion doubles the capacity of ambient pallet storage at 15°C to 30°C
GHO Capital and The Vistria Group to acquire Alcami, a leading high growth CDMO, from Madison...
Morrisville, North Carolina – September 22, 2022 – Alcami, a U.S.-based pharmaceutical contract...
Wilmington, N.C. – May 3, 2022 – Alcami, a leading United States-based contract development and...
With today’s growing pipeline of biologics, namely complex oncology products often delivered...
Morrisville, North...
As a proud member of the Drug, Chemical & Associated Technologies Association, Alcami is pleased to...
An increasing number of clinical trial registrations, more R&D investment, growing demand for...
Read this case study to learn how Alcami supported Carolina Components Group in the successful...
Acquisition to add 375,000 ft² of cGMP Biostorage and Pharma Support Services
DURHAM, N.C. – November 16, 2021 – Alcami, a leading United States-based contract development and...
DURHAM, N.C. – October 12, 2021 - Alcami, a leading United States-based contract development and...
CHARLESTON, S.C. – September 29, 2021 - Alcami, a leading United States-based contract development...
Recently, contract development and manufacturing organizations (CDMOs) involved in the...
Client Profile
The client needed formulation development of an oral dosage form from scratch. They...
As opposed to traditional drug production, the production of biological products (biologics)...
According to the Food and Drug Administration and the Orphan Drug Designation program, orphan...
The agreement represents another step toward the proprietary manufacturing, formulation, and...
Combination products are becoming increasingly important to pharmaceutical CDMOs like Alcami, said...
From standalone projects through full-service programs, our laboratories provide solutions to your...
Wilmington, N.C. – March 18, 2021 – Alcami, a global pharmaceutical contract development and...
You're invited to take part in a now on demand webinar. During this webinar, regulatory and quality...
The global pharmaceutical analytical testing outsourcing market was estimated at $6.1 billion in...
Alcami, a leading United States-based contract development and manufacturing organization...
Although there is no such thing as a truly “crisis-proof” organization, how are you working to...
Today’s technology has not only changed the way we receive information, but has continually adapted...
A holistic approach to validation and quality assurance is essential.
Biologic drugs are highly...
You're invited to attend our on demand virtual event. During this webinar, scientific experts will ...
Global contract development and manufacturing organisation (CDMO), Sterling Pharma...
We're kicking off the opening of our new formulation and sterile fill-finish facility with a...
Alcami’s scientists have substantial experience designing and executing food interaction studies...
MORRISVILLE, N.C., July 28, 2020 -- Alcami, a US-based contract development and manufacturing...
In recent years 505(b)(2) approvals have experienced double-digit growth. Many companies are...